Hormone receptor–positive (HR+) breast cancers (BCs) are typically “immune-cold,” poorly immune-infiltrated tumors that do not respond to immune-checkpoint blockade (ICB) therapies. The gene discussed is NR4A1; the disease is breast cancer.